Studies have indicated that prolonged exposure to BRAF/MEK inhibitors renders melanomas less dependent on glycolysis but addicted to mitochondrial metabolism and anaplerotic pathways, such as glutaminolysis [21,22]. This evidence concerns the gene MAP2K7 and melanoma.